Compare · ABT vs PTPI
ABT vs PTPI
Side-by-side comparison of Abbott Laboratories (ABT) and Petros Pharmaceuticals Inc. (PTPI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and PTPI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.90B, about 4562.8x PTPI ($33.5M).
- Over the past year, ABT is down 34.3% and PTPI is up 0.0% - PTPI leads by 34.3 points.
- ABT has been more active in the news (4 items in the past 4 weeks vs 1 for PTPI).
- ABT has more recent analyst coverage (25 ratings vs 0 for PTPI).
- Company
- Abbott Laboratories
- Petros Pharmaceuticals Inc.
- Price
- $87.73+2.52%
- $0.06-50.66%
- Market cap
- $152.90B
- $33.5M
- 1M return
- -3.20%
- +0.00%
- 1Y return
- -34.34%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 4
- 1
- Recent ratings
- 25
- 0
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Petros Pharmaceuticals Inc.
Petros Pharmaceuticals, Inc. engages in identifying, acquiring, developing, and commercializing therapeutics for men's health issues in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company develops H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. It also offers prescription medication, such as Stendra for the treatment of male erectile dysfunction; and vacuum erection devices. Petros Pharmaceuticals, Inc. is based in New York, New York.
Latest ABT
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
- SEC Form SCHEDULE 13G filed by Abbott Laboratories
- SEC Form 10-Q filed by Abbott Laboratories
- Director Conroy Kevin T was granted 2,286 units of Common shares without par value, increasing direct ownership by 2% to 133,737 units (SEC Form 4)
- New insider Conroy Kevin T claimed ownership of 131,451 units of Common shares without par value (SEC Form 3)
- Director Stratton John G was granted 2,286 units of Common shares without par value, increasing direct ownership by 12% to 21,319 units (SEC Form 4)
Latest PTPI
- SEC Form 10-Q filed by Petros Pharmaceuticals Inc.
- SEC Form 10-K filed by Petros Pharmaceuticals Inc.
- SEC Form NT 10-K filed by Petros Pharmaceuticals Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Petros Pharmaceuticals Inc.
- Officer Boctor Fady was granted 500,000 shares, increasing direct ownership by 2,502% to 519,986 units (SEC Form 4)
- Director Silverman Joshua was granted 4,375,000 shares, increasing direct ownership by 10,816% to 4,415,450 units (SEC Form 4)
- Director Walker Wayne Remell was granted 500,000 shares, increasing direct ownership by 7,895% to 506,333 units (SEC Form 4)
- Petros Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update
- Director Bernstein Bruce was granted 1,875,000 shares, increasing direct ownership by 15,202% to 1,887,334 units (SEC Form 4)
- SEC Form 25-NSE filed by Petros Pharmaceuticals Inc.